HOW DO SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONISTS WORK?
Selective bradykinin B2 receptor antagonist medications are used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE, an immune system disorder). These drugs competitively inhibit bradykinin B2 receptors from binding to bradykinin, a peptide that causes inflammation, thus treating the symptoms of acute HAE attack.
HAE is caused by C1-esterase inhibitor deficiency is an autosomal-dominant disease resulting from a mutation in the C1-inhibitor gene. This deficiency may increase bradykinin concentrations in the plasma. High bradykinin levels cause symptoms of HAE such as inflammation, localized swelling, pain and life-threatening complications such as swelling of the larynx (area of the throat containing the vocal cords).
Icatibant is the only drug approved by the U.S. Food and Drug Administration for the treatment of episodes of HAE.
HOW ARE SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONISTS USED?
Selective bradykinin B2 receptor antagonists are administered subcutaneously to treat acute episodes of swelling and inflammation associated with HAE.
WHAT ARE SIDE EFFECTS OF SELECTIVE BRADYKININ B2 RECEPTOR ANTAGONISTS?
Side effects of selective bradykinin B2 receptor antagonists may include:
The information contained herein is not intended to cover all possible side effects, precautions, warnings, drug interactions, allergic reactions, or adverse effects. Check with your doctor or pharmacist to make sure these drugs do not cause any harm when you take them along with other medicines. Never stop taking your medication and never change your dose or frequency without consulting your doctor.